Global mortality rates resulting from non-communicable diseases (NCDs) are reaching alarming levels with an increase from below 8 million between 1990 and 2010 to 34.5 million during year 2010 \[[@R1]\]. This figure is estimated to reach 52 million by 2030 \[[@R2],[@R3]\]. Notably, low- and middle-income countries (LMICs) witnessed highest percentage increase of NCDs deaths with an expected average of 7 out of every 10 deaths occurring in developing countries by 2020 \[[@R4]\]. Eighty two percent of these deaths are caused by four major NCDs, namely cardiovascular diseases, chronic respiratory diseases (asthma and chronic obstructive pulmonary disease in particular), cancer, and diabetes \[[@R5]-[@R7]\]. Consistent with global trend, the Arab region was witnessing an increasing NCDs burden \[[@R8]\]. In Lebanon, 85% of deaths are attributed to NCDs \[[@R9],[@R10]\], while in Morocco and Kuwait, NCDs account for 75% and 73% of deaths, respectively \[[@R11],[@R12]\]. Furthermore, while deaths caused by infectious diseases are declining in the West, some countries in the region still carry a double burden of disease like Sudan, where 34% of deaths are attributable to NCDs, and 53% still result from communicable diseases \[[@R12],[@R13]\]. The latter challenge of dealing with multiple diseases is intensified by several factors: limited human and financial resources, weak surveillance system, limited access to health care services and lack of financial protection in terms of insurance or public funding \[[@R14]\].

Worldwide, the rising burden of death and disability attributed to NCDs threatens the functionality and effectiveness of the health sector and imposes risks on economic stability and development of societies \[[@R15],[@R16]\]. In several developed and developing countries, health costs and productivity loss associated with management of diabetes alone represent a significant share of gross domestic product (GDP), reaching 1% share from the US economy \[[@R17]\]. Economists are expressing major concerns about the long-term macroeconomic impact of NCDs on capital accumulation and GDP worldwide, with most severe consequences likely to be felt by developing countries \[[@R18]\]. In fact, it is estimated that NCDs costs will reach more than US\$ 30 trillion in the coming two decades \[[@R19]\] further challenging the ability of health care systems to cope with these rising costs, especially in resource-scarce countries \[[@R18]\].

Considerable literature exists on economic evaluation and costs associated with NCDs in different regions worldwide, mostly in high-income countries (HICs) \[[@R20]-[@R23]\]. However, to date, no such studies exist in LMICs \[[@R4],[@R24]-[@R27]\] and minimal effort was undertaken to synthesize and analyze current evidence addressing this issue in a comprehensive review \[[@R28]-[@R30]\]. Additionally, there has not been any attempt to collate and review relevant literature and evaluate the quality of existing studies on NCDs' cost in the Arab region. This study aims to identify and synthesize available published evidence evaluating the cost associated with management and treatment of major NCDs across all Arab countries; to appraise critically these studies' quality; and to identify the gap in existing literature. This study's findings will aid in building a profile of the financial burden of NCDs in the Arab region, which would support and direct health care planning and future health research.

METHODS
=======

Search strategy and inclusion criteria
--------------------------------------

A systematic search was conducted using Medline electronic database to identify and retrieve articles evaluating the cost associated with management of NCDs in all 22 Arab countries; namely: Algeria, Bahrain, Comoros, Djibouti, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, United Arab Emirates and Yemen. Based on their global economic burden on governments and populations, the following NCDs were selected: cardiovascular diseases, cancer, chronic respiratory diseases and diabetes \[[@R31]\]. Only papers published in English between January 2000 and April 2016 inclusive were included. The complete search strategy applied in this review is available in Appendix S1 of **Online Supplementary Document[(Online Supplementary Document)](#S1){ref-type="supplementary-material"}**, and key inclusion and exclusion criteria are presented in [**Figure 1**](#F1){ref-type="fig"}. The search strategy used MeSH terms and keywords relative to each of the four NCDs, their risk factors and costing including: Tobacco, Nutrition/Diet, Alcohol and Substance Abuse, Physical Inactivity, Hypertension, Cholesterol, Hyperlipidemia, Metabolic Syndrome, Salt and Sodium Intake, Diabetes, Cardiovascular disease, Cancer, Chronic Lung Dysfunction, Asthma, COPD, Renal Dysfunction, and Chronic Diseases, Health Care Costs, Health Expenditure, Health Resources, Insurance, Reimbursement, Fees, Charges, Feasibility Studies and Cost Benefit Analysis. The terms were combined with each of the 22 countries in the Arab region. Retrieved articles were screened and reviewed to assess their eligibility based on their content and study population. A total of 725 papers were identified to fit the initial search criteria. After removing duplicates, 707 papers remained for further screening.

![Flowchart of articles identified, included and excluded.](jogh-08-020410-F1){#F1}

Study selection
---------------

Titles and abstracts of the initially identified articles were screened by two independent reviewers to assess whether they fulfill the selection criteria using keywords including cost/costing, feasibility, utilization, finance/financing, payment, reimbursement, coverage and charge, expenses, monetary outcomes and resource investment. Articles not including any of the above-mentioned keywords in the title or abstract were excluded. Hence, 534 articles were identified for full text review and were assessed by the two reviewers for relevance with regard to the research topic. Only those articles that provided direct quantification of costs associated with NCDs, their treatment, management, or risk factors within the target countries were included. Studies conducted outside of Arab region were excluded. Any disagreement between the two reviewers was resolved by discussion and consensus or through consultation with a third reviewer when needed. The identified eligible articles accounted for a total of 55 articles, tackling the issue of NCDs' costs within at least one of the Arab countries.

Data abstraction
----------------

Data was extracted from full texts included in this review using a data collection form composed of the following criteria ([**Table 1**](#T1){ref-type="table"}):

###### 

Overview of the characteristics of the studies included in this scoping review\*

  Source                                Year of publication/ year for cost data   Country                                                        Study design                                                  Sample size                                                                                                                                                           NCD addressed                                          Source of data
  ------------------------------------- ----------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------
  Aďt-Khaled et al \[[@R32]\]           2000/1998                                 Algeria and Syria                                              Cross-sectional                                               10 countries                                                                                                                                                          Asthma                                               Health system
  Al Khaja et al \[[@R33]\]             2001/1998                                 Bahrain                                                        Cross-sectional                                               3838 patients                                                                                                                                                         Hypertension                                         Primary health care centers
  Caro et al \[[@R34]\]                 2002/1999                                 Egypt and Jordan                                               Cross-sectional                                               10 countries, 199 and 232 patients (from patient membership lists) from Egypt and Jordan respectively with patients less than 10 y old being the largest age group.   Thalassemia Major                                    Health system
  Behbehani and Al-Yousifi \[[@R35]\]   2003/1996                                 Kuwait                                                         Cross-sectional                                               36 (12 family and 24 non-family) primary health care centers                                                                                                          Asthma                                               Primary health care centers
  Shaheen and Al Khader \[[@R36]\]      2005/2004                                 Kingdom of Saudi Arabia                                        Literature review                                             N/A                                                                                                                                                                   Chronic Renal Failure                                N/A
  Arevian \[[@R37]\]                    2005/2002                                 Lebanon                                                        Prospective follow up                                         375 patients                                                                                                                                                                                                               Primary health care center (socio-medical health center)
  Elrayah et al \[[@R38]\]              2005/2003                                 Sudan                                                          Descriptive cross-sectional                                   Diabetes                                                                                                                                                                                                                   3 public and 3 private clinics
  AlMarri \[[@R39]\]                    2006/2002                                 Qatar                                                          Cross-sectional analysis                                      Childhood diabetes mellitus type 1                                                                                                                                    Asthma                                               Health system
  El-Zawahry et al \[[@R40]\]           2007/1999-2002                            Egypt                                                          Retrospective study                                           82 adult AML patients                                                                                                                                                 Cancer -- AML (acute myeloid leukemia)               Health system (National Cancer Institute)
  Batieha et al \[[@R41]\]              2007/2003                                 Jordan                                                         Cross-sectional                                               1711 patients                                                                                                                                                         Chronic Renal Failure                                Health system (56 hemodialysis units)
  Abdel-Rahman et al \[[@R42]\]         2008/2003-2007                            Jordan                                                         Review                                                        320 patients                                                                                                                                                          Cancer                                               Cancer center
  Ali et al \[[@R43]\]                  2008/2007                                 Kingdom of Saudi Arabia                                        Prospective observational study & computer simulation model   598 patients                                                                                                                                                          Diabetes                                             Health system
  Dennison et al \[[@R44]\]             2008/2006                                 Sultanate of Oman                                              Cohort study                                                  128 patients                                                                                                                                                          Hematologic disorders                                University hospital
  El-Zimaity et al \[[@R45]\]           2008/2005-2008                            Egypt                                                          Cohort study                                                  16 patients                                                                                                                                                           Hematologic disorders                                University Bone Marrow Transplant Unit
  Strzelczyk et al \[[@R46]\]           2008/2006                                 Sultanate of Oman                                              Systematic Review                                             486 patients aged \>13 years                                                                                                                                          Epilepsy                                             Hospital
  Al-Naggar et al \[[@R47]\]            2009/2008                                 Yemen                                                          Cross-sectional study                                         105 female doctors                                                                                                                                                    Breast cancer                                        Four main hospitals in capital
  Sabry et al \[[@R48]\]                2009/2008                                 Kingdom of Saudi Arabia                                        Cross-sectional study                                         23 adult chronic renal failure patients stabilized on hemodialysis                                                                                                    Chronic renal failure                                Health system
  Sweileh et. al \[[@R49]\]             2009/2006                                 Palestine                                                      Descriptive study                                             95 patients                                                                                                                                                           Cardiovascular (ischemic stroke)                     Hospital
  Shams & Barakat \[[@R50]\]            2010/2008                                 Egypt                                                          Cross-sectional study                                         226 patients                                                                                                                                                          Diabetes                                             University hospital
  Al-Maskari \[[@R51]\]                 2010/2005                                 United Arab Emirates                                           Cross-sectional study                                         150 patients                                                                                                                                                          Diabetes                                             Two hospitals
  Boutayeb et al \[[@R52]\]             2010/2007                                 Morocco                                                        Cost analysis                                                 N/A                                                                                                                                                                   Breast cancer                                        Country
  Denewer et al \[[@R53]\]              2010/2007                                 Egypt                                                          Cross-sectional study                                         5900 women                                                                                                                                                            Breast cancer                                        Rural areas
  Elrayah-Eliadarous et al \[[@R54]\]   2010/2005                                 Sudan                                                          Cross-sectional study                                         822 patients                                                                                                                                                          Diabetes                                             Public and private diabetes clinics
  Valentine et al \[[@R55]\]            2010/2008                                 Kingdom of Saudi Arabia                                        Systematic Review                                             598 patients                                                                                                                                                          Diabetes                                             Health system
  Farag et al \[[@R56]\]                2011/2010                                 Egypt and Kingdom of Saudi Arabia                              Review                                                        NA                                                                                                                                                                    Diabetes                                             Health system
  Osman et al \[[@R57]\]                2011/2009                                 Kingdom of Saudi Arabia                                        Prospective observational study                               205 patients                                                                                                                                                          Cardiovascular (ischemic heart disease)              Major cardiac center
  Alameddine & Nassir \[[@R58]\]        2012/2010                                 Kingdom of Saudi Arabia                                        Retrospective study                                           516 patients                                                                                                                                                          Bladder cancer                                       Medical center
  Berraho et al \[[@R59]\]              2012/2009                                 Morocco                                                        Cohort study                                                  1978 new cases                                                                                                                                                        Cervical cancer                                      Health system
  Soliman & Roshd \[[@R60]\]            2012/2010                                 Egypt                                                          Cross-sectional study                                         155 patients                                                                                                                                                          End-stage renal disease                              Nephrology centers
  Tachfouti et al \[[@R61]\]            2012/2004                                 Morocco                                                        Cross-sectional study                                         3500 new cases                                                                                                                                                        Lung cancer                                          Health system
  Al-Busaidi et al \[[@R62]\]           2013/2010                                 Sultanate of Oman                                              Cost analysis                                                 91 646 adults and 55 426 children                                                                                                                                     Asthma                                               Health system
  Algahtani et al \[[@R63]\]            2013/2010                                 Kingdom of Saudi Arabia                                        Prospective randomized clinical study                         103 patients                                                                                                                                                          Deep vein thrombosis                                 Tertiary care hospital
  Alhowaish \[[@R64]\]                  2013/2010                                 Kingdom of Saudi Arabia                                        Cross-sectional study                                         3.4 million patients                                                                                                                                                  Diabetes                                             Health system
  Almutairi and Alkharfy \[[@R65]\]     2013/2010-2011                            Kingdom of Saudi Arabia                                        Retrospective observational study                             300 patients                                                                                                                                                          Diabetes                                             University hospital
  Al-Rubeaan et al \[[@R66]\]           2013/2012                                 Kingdom of Saudi Arabia                                        Descriptive study                                             84 942 patients                                                                                                                                                       Diabetes                                             Saudi National Diabetes Registry
  Al-Sharayri et al \[[@R67]\]          2013/2012                                 Jordan                                                         Cross-sectional study                                         556 prescriptions                                                                                                                                                     Diabetes                                             Outpatient pharmacy in a medical center
  Al-Shdaifat and Manaf \[[@R68]\]      2013/2010                                 Jordan                                                         Cross-sectional study                                         175 patients                                                                                                                                                          Chronic Renal Failure                                3 Hospitals
  Ghanname et al \[[@R69]\]             2013/2010                                 Morocco                                                        Cost analysis                                                 N/A                                                                                                                                                                   Asthma                                               Health system
  Khadadah \[[@R70]\]                   2013/2005                                 Kuwait                                                         Cost analysis                                                 93 923 adult patients and 70 158 children patients                                                                                                                    Asthma                                               Health system
  Alzaabi et al \[[@R71]\]              2014/2011                                 United Arab Emirates                                           Retrospective study                                           139 092 patients                                                                                                                                                      Asthma                                               Health system
  Ghanname et al \[[@R72]\]             2014/2010                                 Morocco                                                        Cost analysis                                                 N/A                                                                                                                                                                   Asthma                                               Health system
  Lamri et al \[[@R73]\]                2014/2013                                 Algeria                                                        Literature review                                             N/A                                                                                                                                                                   Diabetes                                             Health system
  Mason et al \[[@R74]\]                2014/2010                                 Tunisia, Syria and Palestine                                   Cost-effectiveness analysis                                   N/A                                                                                                                                                                   Coronary heart disease                               Health system
  Isma\'eel et al \[[@R75]\]            2012/2011                                 Lebanon, Bahrain, Jordan, Kuwait, Saudi Arabia, UAE and Oman   Descriptive study                                             N/A                                                                                                                                                                   Coronary heart disease                               Health system
  Younis et al \[[@R76]\]               2011/2008                                 Palestine                                                      Cost analysis                                                 N/A                                                                                                                                                                   Coronary heart disease                               Tertiary care hospital
  Shafie et al \[[@R77]\]               2014/2010                                 Algeria and Kingdom of Saudi Arabia                            Cost-effectiveness analysis                                   279 and 901 respectively                                                                                                                                              Diabetes                                             Health system
  Al-Busaidi et al \[[@R78]\]           2015/2013                                 Sultanate of Oman                                              Commentary                                                    N/A                                                                                                                                                                   Asthma                                               Health system
  Al-Kaabi & Atherton \[[@R79]\]        2015/2010                                 Qatar                                                          Review                                                        N/A                                                                                                                                                                   4 NCDs (cancer, cardiovascular, COPD and diabetes)   Health system
  Antar et al \[[@R80]\]                2015/2011                                 Lebanon                                                        Retrospective analysis                                        83 patients                                                                                                                                                           Cancer (multiple myeloma)                            Tertiary care hospital
  Eltabbakh et al \[[@R81]\]            2015/2011                                 Egypt                                                          Prospective, single-center cohort study                       1286 patients                                                                                                                                                         Liver cirrhosis                                      Tertiary care hospital
  Gupta et al \[[@R82]\]                2015/2013                                 Kingdom of Saudi Arabia                                        Cost-effectiveness analysis                                   680 patients                                                                                                                                                          Diabetes                                             Health system
  Home et al \[[@R83]\]                 2015/2013                                 Algeria                                                        Cost-effectiveness analysis                                   473 patients                                                                                                                                                          Diabetes                                             Health system
  Schubert et al \[[@R84]\]             2015/2015                                 United Arab Emirates                                           Network meta-analysis                                         N/A                                                                                                                                                                   Diabetes                                             Health system
  Thaqafi et al \[[@R85]\]              2015/2015                                 Kingdom of Saudi Arabia                                        Cost analysis                                                 N/A                                                                                                                                                                   Hematologic cancer                                   Health system
  Ahmad et al \[[@R86]\]                2016/2014                                 Sultanate of Oman                                              Retrospective study                                           50 adult cardiac arrest patients who had undergone CPR                                                                                                                Cardiac arrest                                       Hospital

CPR -- cardiopulmonary resuscitation, NCD -- non-communicable disease, COPD-- Chronic obstructive pulmonary disease

\*N/A refers to not applicable whereby the data of interest is not specified in the respective reference.

-   Country -- based on study location;

-   Category -- based on main theme/topic addressed: management of the NCD, treatment/medication, or procedure;

-   Study design -- classified as cross-sectional, cohort, review, or systematic review/meta-analysis;

-   Setting -- described as being a health system, cases from primary healthcare center, hospital, or clinic (private vs. public);

-   Population/Sample size;

-   Year of publication;

-   Year for cost data;

-   Costing approach -- classified as bottom up or top down;

-   Costing perspective -- classified as societal, governmental, provider or patient;

-   Type of costs -- classified as direct medical, indirect medical and indirect;

-   Source of information -- classified as survey, medical record, health information survey or electronic database.

The findings are presented by type of NCD. US\$ were used when assessing economic costs across all studies to enhance comparability. Other reported local currencies were converted to US\$ based on the exchange rate specified by the corresponding study. When exchange rate was not mentioned, conversion to US\$ was performed using the conversion rate specific to the year of publication of the study.

Quality evaluation
------------------

The quality of included cross-sectional, case-control and cohort studies was evaluated using the Newcastle--Ottawa Scale (NOS), which is based on three domains: selection, comparability and exposure \[[@R87]\]. A maximum of one star can be awarded to each question in the selection category and one star to each question included in the exposure category, while a maximum of two stars can be awarded to a single question in the comparability section. For each study, a quality score is then generated by adding up the number of stars given and would not exceed 9 stars. The modified version of the NOS used for descriptive and cross-sectional studies was adopted from the systematic review conducted by Jaspers et al (2015) \[[@R88]\].

RESULTS
=======

We initially identified 725 potentially eligible references published between 2000 and 2016 ([**Figure 1**](#F1){ref-type="fig"}). Of those, and after title and abstract and full text screenings, 55 studies met the inclusion criteria and were thoroughly described in the review.

Overview of included studies
----------------------------

The reviewed articles covered most of the Arab region, yet no data was available from 6 of the 22 Arab countries, namely Iraq, Somalia, Libya, Mauritania, Djibouti and Comoros. The majority of studies (n = 27) originated from high-income Arab countries, while 19 were conducted in lower-middle income and 12 were from upper-middle income Arab countries. This reflected GDP variation across the reviewed articles. Most studies were conducted in the Kingdom of Saudi Arabia (n = 15), Egypt (n = 8) and Jordan (n = 7) whereas 5 studies were conducted in multiple countries ([**Table 1**](#T1){ref-type="table"}). Included studies were mainly observational with retrospective or prospective design, few other studies were modeling, reviews, systematic reviews, meta-analyses, commentaries and cost analyses. In 30 studies, the setting represented was the health system. The remaining studies sampled eligible participants from hospitals (n = 15), medical centers (n = 5), primary health care centers (n = 3) and private and public clinics (n = 2) ([**Table 1**](#T1){ref-type="table"}).

The most frequently studied NCD was diabetes (n = 18) whereas chronic respiratory diseases (mainly asthma, n = 9) and cancer were each analyzed in 11 studies. Twelve studies focused on cost associated with management of cardiovascular diseases while 7 studies focused on other NCDs mainly chronic renal failure ([**Table 1**](#T1){ref-type="table"}). Only one study addressed the four NCDs together.

All of the included studies reported direct medical costs associated with the management of the four major non-communicable diseases in the Arab region. Some studies (n = 15) also included indirect costs such as loss of productivity and premature death. While only one article described direct non-medical costs that are not directly related to medical services such as transportation. ([**Table 4**](#T4){ref-type="table"}).

###### 

Results indicating cost associated with the management of other NCDs reported in the included studies

  Source                             Country                   Addressed NCD             Population studied /contacted                                     Category/ Costing Scope   Outcome specified as                                                                                                                                                                                                                               Point estimate (in US\$)                                                  Quality score
  ---------------------------------- ------------------------- ------------------------- ----------------------------------------------------------------- ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ---------------
  Shaheen and Al Khader \[[@R36]\]   Kingdom of Saudi Arabia   Chronic renal failure     NA                                                                Procedure                 Annual cost incurred toward maintenance hemodialysis                                                                                                                                                                                               19 400                                                                    NA
  Batieha et al \[[@R41]\]           Jordan                    Chronic renal failure     Patients on hemodialysis                                          Procedure                 Total annual cost of hemodialysis including hemodialysis sessions, medications and investigations, admissions and arterial access                                                                                                                  29 715 553                                                                4
  Strzelczyk et al \[[@R46]\]        Sultanate of Oman         Epilepsy                  Patients aged \>13 years old                                      Management                \% attributed to inpatient admission                                                                                                                                                                                                               52%                                                                       NA
  Sabry et al \[[@R48]\]             Kingdom of Saudi Arabia   Chronic renal failure     Adult chronic renal failure patients stabilized on hemodialysis   Treatment                 Mean cost of 6 mo use of (1) tinzaparin sodium per patient compared to that of (2) unfractionated heparins                                                                                                                                         \(1\) 67.57 and (2) 51.23                                                 2
  Soliman & Roshd \[[@R60]\]         Egypt                     End-stage renal disease   Chronic renal failure patients                                    Management                \(1\) annual cost for thrice-weekly hemodialysis, (2) cost of CAPD catheter insertion, (3) annual cost of 3 to 4 fluid exchanges, (4) costs for pre-transplantation and transplantation procedures, (5) annual costs for immunosuppressive drugs   \(1\) 3250, (2) 150, (3) \[4500-6000\], (4) 6000-7500 and (5) 3250-6000   1
  Al-Shdaifat and Manaf \[[@R68]\]   Jordan                    Chronic renal failure     Chronic renal failure patients                                    Procedure                 \(1\) total annual cost at MOH and (2) annual cost per patient                                                                                                                                                                                     (1)17.7 million and (2) 9976                                              3
  Eltabbakh et al \[[@R81]\]         Egypt                     Liver cirrhosis           Liver cirrhosis patients                                          Procedure                 Annual cost of detecting a treatable HCC case by (1) ultrasound and (2) by both ultrasound and AFP                                                                                                                                                 \(1\) 560 and (2) 650                                                     2

MOH -- Ministry of Health, HCC -- Hepatocellular carcinoma, AFP --Alpha-fetoprotein, CAPD -- Continuous ambulatory peritoneal dialysis

\*N/A refers to "not applicable" whereby the data of interest is not specified in the respective reference.

Cost data collected through surveys represented the most commonly used data source (n = 19) while 12 studies relied on data retrieved from health information systems of ministries, hospitals and insurance companies followed by prior estimates published in the literature, which is represented as electronic database (n = 12) in [**Table 5**](#T5){ref-type="table"}. Medical records were used in eight studies and a data source was not applicable for the component costs of one study. Some studies included several cost components and data sources without giving a clear description of which data sources were used for particular components.

###### 

Results indicating costing approach, costing perspective, type of costs and sources of information associated with the management of the NCDs reported in the included studies\*

  Source                                Year   Costing approach         Costing perspective         Type of costs                                Sources of information\*
  ------------------------------------- ------ ------------------------ --------------------------- -------------------------------------------- ---------------------------
  Aďt-Khaled et al \[[@R32]\]           2000   Bottom up                Governmental                Direct medical and indirect                  Survey
  Al Khaja et al \[[@R33]\]             2001   Bottom up                Societal                    Direct medical                               Survey
  Caro et al \[[@R34]\]                 2002   N/A                      Patient                     Direct medical and indirect                  Survey
  Behbehani and Al-Yousifi \[[@R35]\]   2003   Top down                 Provider                    Direct medical                               Survey
  Shaheen and Al Khader \[[@R36]\]      2005   N/A                      Governmental                Direct medical                               NA
  Arevian \[[@R37]\]                    2005   N/A                      Provider                    Direct medical and indirect                  Medical record
  Elrayah et al \[[@R38]\]              2005   Bottom up                Provider                    Direct medical and indirect                  Survey
  Al Marri \[[@R39]\]                   2006   Bottom up                Provider                    Direct medical                               Health information system
  El-Zawahry et al \[[@R40]\]           2007   Bottom up                Patient                     Direct medical                               Medical record
  Batieha et al \[[@R41]\]              2007   Bottom up                Patient                     Direct medical                               Survey
  Abdel-Rahman et al \[[@R42]\]         2008   Bottom up                Provider                    Direct medical                               Medical record
  Ali et al \[[@R43]\]                  2008   Bottom up                Provider                    Direct and indirect medical cost             Survey
  Dennison et al \[[@R44]\]             2008   Top down                 Provider                    Direct medical                               Medical record
  El-Zimaity et al \[[@R45]\]           2008   N/A                      Patient                     Direct medical                               Medical record
  Strzelczyk et al \[[@R46]\]           2008   Bottom up                Patient                     Direct medical and indirect                  Electronic databases
  Al-Naggar et al \[[@R47]\]            2009   N/A                      Provider                    Direct medical                               Survey
  Sabry et al \[[@R48]\]                2009   N/A                      Patient                     Direct medical                               Survey
  Sweileh et. al \[[@R49]\]             2009   Bottom up                Patient                     Direct medical                               Survey
  Shams & Barakat \[[@R50]\]            2010   N/A                      Patient                     Direct medical and indirect                  Survey
  Al-Maskari \[[@R51]\]                 2010   Bottom up                Patient                     Direct medical                               Survey
  Boutayeb et al \[[@R52]\]             2010   Bottom up                Provider                    Direct medical                               Secondary data
  Denewer et al \[[@R53]\]              2010   Bottom up                Patient                     Direct medical                               Survey
  Elrayah-Eliadarous et al \[[@R54]\]   2010   Top down                 Patient                     Direct medical                               Survey
  Valentine et al \[[@R55]\]            2010   Bottom up                Provider                    Direct medical                               Electronic databases
  Farag et al \[[@R56]\]                2011   Bottom up                Provider                    Direct medical                               Electronic databases
  Osman et al \[[@R57]\]                2011   Bottom up                Provider                    Direct medical                               Medical record
  Alameddine & Nassir \[[@R58]\]        2012   Top down                 Provider                    Direct medical                               Medical record
  Berraho et al \[[@R59]\]              2012   Bottom up                Patient                     Direct medical                               Health information system
  Soliman & Roshd \[[@R60]\]            2012   Bottom up                Patient                     Direct medical                               Survey
  Tachfouti et al \[[@R61]\]            2012   Bottom up                Governmental                Direct medical                               Health information system
  Al-Busaidi et al \[[@R62]\]           2013   Bottom up                Patient                     Direct medical                               Electronic databases
  Algahtani et al \[[@R63]\]            2013   Bottom up                Provider                    Direct medical                               Health information system
  Alhowaish \[[@R64]\]                  2013   Top down                 Governmental                Direct medical                               Health information system
  Almutairi and Alkharfy \[[@R65]\]     2013   Bottom up                Governmental                Direct medical                               Health information system
  Al-Rubeaan et al \[[@R66]\]           2013   Bottom up                Governmental                Direct medical                               Health information system
  Al-Sharayri et al \[[@R67]\]          2013   Bottom up                Provider                    Direct medical                               Medical record
  Al-Shdaifat and Manaf \[[@R68]\]      2013   Bottom up and top down   Provider                    Direct medical and nonmedical and indirect   Health information system
  Ghanname et al \[[@R69]\]             2013   Bottom up                Patient                     Direct medical                               Health information system
  Khadadah \[[@R70]\]                   2013   Bottom up                Patient                     Direct medical                               Survey
  Alzaabi et al \[[@R71]\]              2014   Bottom up                Government                  Direct medical                               Health information system
  Ghanname et al \[[@R72]\]             2014   Bottom up                Patient                     Direct medical                               Health information system
  Lamri et al \[[@R73]\]                2014   Top down                 Patient                     Direct medical and indirect                  Electronic databases
  Mason et al \[[@R74]\]                2014   Top down                 Governmental and Provider   Direct medical and indirect                  Survey
  Younis et al \[[@R76]\]               2011   N/A                      Provider                    Direct medical                               Health information system
  Isma\'eel et al \[[@R75]\]            2012   N/A                      Patient                     Direct medical                               Electronic databases
  Shafie et al \[[@R77]\]               2014   Bottom up                Patient                     Direct medical and indirect                  Survey
  Al-Busaidi et al \[[@R78]\]           2015   Bottom up                Patient                     Direct medical                               Electronic databases
  Al-Kaabi & Atherton \[[@R79]\]        2015   Top down                 Societal                    Direct medical and indirect                  Electronic databases
  Antar et al \[[@R80]\]                2015   Bottom up                Provider                    Direct medical                               Health information system
  Eltabbakh et al \[[@R81]\]            2015   Bottom up                Patient                     Direct medical and indirect                  Survey
  Gupta et al \[[@R82]\]                2015   Bottom up                Societal                    Direct medical and indirect                  Electronic database
  Home et al \[[@R83]\]                 2015   Bottom up                Societal                    Direct medical and indirect                  Electronic database
  Schubert et al \[[@R84]\]             2015   Bottom up                Provider                    Direct medical                               Electronic database
  Thaqafi et al \[[@R85]\]              2015   Bottom up                Provider                    Direct medical                               Electronic database
  Ahmad et al \[[@R86]\]                016    Top down                 Patient                     Direct medical                               Health information system

\*N/A refers to "not applicable" whereby the data of interest is not specified in the respective reference.

Among the 55 studies included, 23 (42%) studies described the patient's perspective and 21 (38%) studies described the provider's perspective in estimating the costs highlighting that the majority of the studies focused on the costs that fall on either patients or health care institutions providing health services. Eight studies looked at the governmental costs associated with NCDs. The remaining studies (n = 8) described the societal level costs.

Although most of the studies did not clearly indicate the costing approach used, the overall aim of the cost analysis and the sources of data assisted in determining the costing approaches followed. Most of the studies (n = 36) estimated the costs using a bottom up approach or micro-costing, while only nine studies relied on a top-down approach or gross-costing in their measurements. Only one study reported using both approaches, while identifying the costing approach was not applicable in seven of the included studies.

Quality of the included studies
-------------------------------

The majority of the studies were appointed a quality score (34 of the 55 included studies). In the studies where a quality score was not assigned, the study design and methodology made quality assessment not feasible. The median quality score over all the studies was three out of nine (interquartile range 2-4). Two thirds of the eligible and scored studies scored three points or less, showing that most of the studies were of low to very low quality.

Cardiovascular diseases
-----------------------

As part of a cost-effectiveness analysis by Mason et al (2014) for the implementation of salt reduction policies \[[@R74]\], health care cost of coronary heart diseases (CHD) in Palestine was estimated ([**Table 2**](#T2){ref-type="table"}). The calculation of health care cost of CHDs incorporated standardized unit cost per patient for a number of CHD conditions, namely, acute myocardial infractions (AMI), secondary prevention following AMI, unstable angina, chronic heart failure (treated in a hospital setting, or in the community), and hypertension \[[@R74]\]. Healthcare cost of coronary heart diseases in Palestine was estimated to be US\$ 354 719 519 \[[@R74]\] ([**Table 2**](#T2){ref-type="table"}).

###### 

Results indicating cost associated with the management of the cardiovascular diseases and cancer reported in the included studies

  Source                           Country                                                                                      Addressed NCD                                                                 Population studied/contacted                                                                                            Category/ Costing Scope               Outcome specified as                                                                                                                                                      Point estimate (in US\$)                                                                                                                           Quality score
  -------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  **Cardio-vascular diseases:**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Al Khaja et al \[[@R33]\]        Bahrain                                                                                      Hypertension                                                                  Patients with uncomplicated essential hypertension                                                                      Medication                            Monthly cost of an antihypertensive drug (indapamine)                                                                                                                     7.7                                                                                                                                                4
  Caro et al \[[@R34]\]            Egypt and Jordan                                                                             Thalassemia major                                                             Patients or their caregivers if less than 14 years old                                                                  Management                            \(1\) % of hospitalized patients with a mean LOS of 10 days during the past 6 months, (2) days missed from employment and (3) days missed from school during 1 month      \(1\) 20%, (2) 2 days and (3) 3 days                                                                                                               3
  Dennison et al \[[@R44]\]        Sultanate of Oman                                                                            Hematologic disorders                                                         Patients who need hematopoietic stem cell transplant                                                                    Procedure                             Approximate cost per uncomplicated transplant                                                                                                                             50 000                                                                                                                                             2
  El-Zimaity et al \[[@R45]\]      Egypt                                                                                        Hematologic disorders                                                         Patients with chronic or acute myeloid leukemia, aplastic anemia, acute lymphoblastic leukemia or aggressive lymphoma   Procedure                             Average estimate cost per transplant                                                                                                                                      8446                                                                                                                                               1
  Sweileh et. al \[[@R49]\]        Palestine                                                                                    Ischemic stroke                                                               Stroke patients                                                                                                         Treatment (therapy and medications)   Average monthly cost for treatment of post-stroke complications                                                                                                           52                                                                                                                                                 6
  Osman et al \[[@R57]\]           Kingdom of Saudi Arabia                                                                      Ischemic heart disease (IHD)                                                  Patients diagnosed or suspected to have IHD                                                                             Management                            Average direct cost (medication, hospital bed use and procedure) per patient                                                                                              10 710                                                                                                                                             4
  Algahtani et al \[[@R63]\]       Kingdom of Saudi Arabia                                                                      Deep vein thrombosis                                                          Symptomatic adult patients with acute proximal DVT of the lower limbs                                                   Treatment                             Mean outpatient treatment cost per case                                                                                                                                   1750                                                                                                                                               3
  Ahmad et al \[[@R86]\]           Sultanate of Oman                                                                            Cardiac arrest                                                                \>18 y old who had cardiac arrest, received at least one attempt at CPR and were potential DNR candidates               Management                            Average cost of post-resuscitation care per patient including cost of medications, laboratory investigations, imaging, minor procedures and hospital stay in ICU or HDU   1958.9                                                                                                                                             5
  Al-Kaabi & Atherton \[[@R79]\]   Qatar                                                                                        Cardiovascular diseases                                                       NA                                                                                                                      Treatment                             Total direct and indirect cost including personal medical; non-medical costs, and income losses                                                                           863 billion                                                                                                                                        NA
  Mason et al \[[@R74]\]           \(1\) Tunisia, (2) Syria and (3) Palestine                                                   Coronary heart disease                                                        NA                                                                                                                      Management                            The total cost saving of having a combination of 3 salt-reduction policies                                                                                                \(1\) 39 000 000, (2) 6 000 000 & (3) 1 300 000                                                                                                    NA
  Isma\'eel et al \[[@R75]\]       \(1\) Lebanon, (2) Bahrain, (3) Jordan, (4) Kuwait, (5) Saudi Arabia, (6) UAE and (7) Oman   Cardiovascular event                                                          Public                                                                                                                  Treatment                             Cost of treatment using 3 types of statins to prevent 1 CV event in 5 years                                                                                               \(1\) 79 388-105 589, (2) 81 505-190 530, (3) 109 578-112 348, (4) 122 786-202 147, (5) 81 323-122 786, (6) 113 260-217 203, (7) 111 143-202,575   1
  Younis et al \[[@R76]\]          Palestine                                                                                    Cardiac catheterization                                                       N/A                                                                                                                     Procedure                             Total cost of unit (medical equipment, salaries, overhead costs, and variable costs)                                                                                      613 544.63                                                                                                                                         NA
  **Cancer:**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  El-Zawahry et al \[[@R40]\]      Egypt                                                                                        Acute myeloid leukemia                                                        Adult AML patients                                                                                                      Treatment                             Median total cost of conventional chemotherapy per case                                                                                                                   5817                                                                                                                                               3
  Abdel-Rahman et al \[[@R42]\]    Jordan                                                                                       Mainly leukemia, nonmalignant hematological disorders and thalassemia major   Transplant patients                                                                                                     Procedure                             Average charge of (1) autologous and (2) allogeneic transplants                                                                                                           \(1\) 35 067 and (2) 66 438                                                                                                                        NA
  Al-Naggar et al \[[@R47]\]       Yemen                                                                                        Breast cancer                                                                 Female OBGYN doctors                                                                                                    Procedure                             \% of doctors who do not send asymptomatic women for screening                                                                                                            23.8% (25 doctors)                                                                                                                                 NA
  Boutayeb et al \[[@R52]\]        Morocco                                                                                      Breast cancer                                                                 NA                                                                                                                      Treatment                             Total cost of breast cancer chemotherapy per case                                                                                                                         13 360                                                                                                                                             NA
  Denewer et al \[[@R53]\]         Egypt                                                                                        Breast cancer                                                                 Women in rural areas                                                                                                    Treatment                             \(1\) cost of screening per cancer case, (2) total cost of treatment for screened cases                                                                                   \(1\) 415 and (2) 1015-1215                                                                                                                        3
  Alameddine & Nassir \[[@R58]\]   Kingdom of Saudi Arabia                                                                      Bladder cancer                                                                Suspected urothelial cancer patients                                                                                    Procedure                             Total cost of 563 urine cytology tests                                                                                                                                    37 533                                                                                                                                             4
  Berraho et al \[[@R59]\]         Morocco                                                                                      Cervical cancer                                                               New cases                                                                                                               Management                            Total cost of care one year after diagnosis                                                                                                                               13 589 360                                                                                                                                         2
  Tachfouti et al \[[@R61]\]       Morocco                                                                                      Lung cancer                                                                   New cases                                                                                                               Management                            Total medical cost                                                                                                                                                        12 million                                                                                                                                         3
  Thaqafi et al \[[@R85]\]         Kingdom of Saudi Arabia                                                                      Hematological cancer                                                          Patients with prolonged neutropenia or undergoing bone marrow or hematopoietic stem-cell transplantation                Medication                            Estimated cost of alternative interventions (1) voriconazole, (2) LAMB, and (3) caspofungin.                                                                              \(1\) 7654, (2) 16 564 and (3) 17 362                                                                                                              N/A
  Antar et al \[[@R80]\]           Lebanon                                                                                      Multiple myeloma                                                              Patients with multiple myeloma performing consecutive hematopoietic stem cell mobilization attempts                     Procedure                             Average cost of (1) chemo-mobilizing and (2) G-CSF and preemptive plerixafor mobilization strategies                                                                      \(1\) 7536 and (2) 7886                                                                                                                            4
  Al-Kaabi & Atherton \[[@R79]\]   Qatar                                                                                        Cancer                                                                        NA                                                                                                                      Management                            Total direct and indirect cost including personal medical; non-medical costs, and income losses                                                                           290 billion in 2010 expected to reach 458 billion in 2030                                                                                          N/A

IHD -- ischemic heart disease, CV -- cardiovascular, DNR -- do not resuscitate, AML -- acute myeloid leukemia, LAMB -- Liposomal Amphotericin B

\*N/A refers to "not applicable" whereby the data of interest is not specified in the respective reference.

A second study from Palestine also quantified costs associated with treating cardiovascular diseases; more specifically, the study estimated total cost of the cardiac catheterization unit in a major governmental hospital in Palestine as part of cost-volume-profit analysis \[[@R76]\]. Total cost calculations included fixed costs of medical equipment, furniture and other equipment, staff salaries, and overhead costs, and variable costs related to type of patient diagnosis, and respective procedures. Total unit cost was found to be US\$ 613 544.63, with greatest costs attributed to variable costs of catheterization unit \[[@R76]\].

Isma'eel et al (2011) estimated the cost to the public of preventing a single cardiovascular event focusing on statins in seven Arabic countries and those are Lebanon, Bahrain, Jordan, Kuwait, Saudi Arabia, UAE and Oman \[[@R75]\]. The study compared cost based on defined daily dose, and compared costs of using one of three different statins for prevention. For instance, in Lebanon, the cost to the public was found to range between US\$ 79 388 and US\$ 105 589, depending on the statin used for treatment. In Bahrain, the cost to the public to prevent one cardiovascular event using statins ranged between US\$ 81 505 and US\$ 190 530. Conversely, in Kuwait, the estimated cost to the public ranged between US\$ 122 786 and US\$ 202 147, depending on the statin used for treatment \[[@R75]\].

Cancer
------

Three studies quantified total costs associated with treating or managing cancer (breast, lung, or cervical) to Moroccan health care authorities for up to one year after diagnosis ([**Table 2**](#T2){ref-type="table"}). Boutayeb et al (2010) estimated total cost of breast cancer treatment by chemotherapy for patients in early stages of breast cancer to be between US\$ 13 300 000 and US\$ 28 600 000, based on international guidelines \[[@R52]\]. The upper bound estimation assumes all new cancer cases are treated. These costs were calculated by estimating the number of women in Morocco with breast cancer, and took into consideration alternative treatment protocols, per unit and per whole cycle \[[@R52]\]. Tachfouti et al (2012) conducted similar calculations to quantify direct costs of managing lung cancer in Morocco \[[@R61]\]. Taking into consideration the incidence of lung cancer, by stage, in the Moroccan population, also, taking into consideration treatment protocols as per international guidelines for each stage of lung cancer, the authors estimated that total medical costs of lung cancer are approximately US\$ 12 000 000 \[[@R61]\]. Berraho et al (2012) used a similar methodology to Tachfouti et al (2012) to calculate total costs of managing cervical cancer in Morocco \[[@R59],[@R61]\]. After estimating the incidence of cervical cancer cases, by stage, in the Moroccan population, and costs of management based on whole-cycle sets, the authors estimated total cost of cervical cancer care to be US\$ 13 589 360.

Diabetes mellitus
-----------------

Elrayah et al (2005) calculated annual direct costs to diabetic children attending public and private diabetes clinics in Sudan, that were associated with controlling diabetes mellitus type 1 \[[@R54]\] ([**Table 3**](#T3){ref-type="table"}). The authors estimated the annual direct cost per diabetic child to be US\$ 283 including costs of insulin, blood and urine tests and hospital admission and doctors' fees. In 2010, the authors conducted a survey to determine out-of-pocket contributions made by patients with diabetes mellitus type 2 on ambulatory care and medications used to control diabetes, and found that annual direct cost per patient was approximately US\$ 175. Patients aged 65 years and older made the greatest out-of-pocket contributions; furthermore, patients receiving ambulatory outpatient care at private clinics paid significantly more for clinic visits compared to patients receiving care at public facilities \[[@R54]\].

###### 

Results indicating cost associated with the management of diabetes and chronic respiratory diseases reported in the included studies\*

  Source                                Country                                          Addressed NCD   Population studied/ contacted                                                                        Category/costing scope   Outcome specified as                                                                                                                                             Point estimate (in US\$)                                                       Quality score
  ------------------------------------- ------------------------------------------------ --------------- ---------------------------------------------------------------------------------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------
  **Diabetes:**                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Arevian \[[@R37]\]                    Lebanon                                          Diabetes        Diabetic patients                                                                                    Management               Annual direct health care cost per a fully complaint case                                                                                                        125 compared to 481 in a tertiary care center                                  2
  Elrayah et al \[[@R34]\]              Sudan-Khartoum                                   Diabetes        Parents of diabetic children                                                                         Management               Annual direct cost per case (including insulin, blood and urine tests, hospital admission and doctors\' fee)                                                     283                                                                            1
  Ali et al \[[@R43]\]                  Kingdom of Saudi Arabia                          Diabetes        Patients with diabetes that were inadequately controlled on their current therapy of human insulin   Treatment                \(1\) annual direct cost of diabetes, (2) direct medical cost savings per patients for conversion from human insulin to BIAsp 30 therapy                         \(1\) 400-700 million and (2) 14 547                                           3
  Shamsa & Barakat \[[@R50]\]           Egypt                                            Diabetes        Patients with diabetes \>18 years old                                                                Treatment                Rate of adherence to medication based on the relation between cost (direct and indirect) and income                                                              57.7% when relation was adequate, 24.8% when relation was not adequate         6
  Al-Maskari \[[@R51]\]                 United Arab Emirates                             Diabetes        Patients with diabetes                                                                               Management               Total annual direct cost of DM (1) without and (2) with (macro and microvascular) complications per case                                                         \(1\) 1605 and (2) 15 104                                                      4
  Elrayah-Eliadarous et al \[[@R54]\]   Sudan                                            Diabetes        Patients with diabetes \>30 y old with a diabetes duration of 1-5 years                              Management               Average annual direct cost (ambulatory care and drugs) of diabetes control per case                                                                              175                                                                            3
  Valentine et al \[[@R55]\]            Kingdom of Saudi Arabia                          Diabetes        Patients with diabetes that were inadequately controlled on their current therapy of human insulin   Treatment                Difference in direct cost between BIAsp and human insulin                                                                                                        15,786                                                                         NA
  Farag et al \[[@R56]\]                Egypt & Kingdom of Saudi Arabia                  Diabetes        NA                                                                                                   Management               Percentage of the country\'s total health expenditure                                                                                                            16% for Egypt and 21% for KSA                                                  NA
  Alhowaish \[[@R64]\]                  Kingdom of Saudi Arabia                          Diabetes        Diabetic patients                                                                                    Management               Total annual national health expenditure                                                                                                                         0.9 billion                                                                    2
  Almutairi and Alkharfy \[[@R65]\]     Kingdom of Saudi Arabia                          Diabetes        Diabetic patients                                                                                    Management               Total annual direct medical cost (drug therapy, diagnostic procedures, hospitalization and outpatient visits)                                                    1,384.19 for HbA1c \<7%; 2036.11 for HbA1c 7%-9%, and 3104.86 for HbA1c \>9%   NA
  Al-Rubeaan et al \[[@R66]\]           Kingdom of Saudi Arabia                          Diabetes        Diabetic patients                                                                                    Medication               Annual insulin cost per patient for (1) Diabetes, (2) DM2 and (3) gestational diabetes                                                                           \(1\) 308, (2) 375 and (3) 267                                                 4
  Al-Sharayri et al \[[@R67]\]          Jordan                                           Diabetes        Patients on (1) traditional vials or (2) cartridges                                                  Medication               Average direct cost per patient                                                                                                                                  \(1\) 7.31 and (2) 31.18                                                       2
  Schubert et al \[[@R84]\]             United Arab Emirates                             Diabetes        Diabetic patients                                                                                    Medication               Cost of canagliflozin (1) 100 and (2) 300 mg equivilant to cost of reaching HbA1c \<7% with dapagliflozin 10 mg per day                                          \(1\) 2.11 and (2) 2.45                                                        NA
  Home et al \[[@R83]\]                 Algeria                                          Diabetes        Patients with diabetes starting insulin detemir                                                      Medication               Direct cost per patient simulated over 30 y with (1) insulin detemir compared to (2) OGLDs alone                                                                 \(1\) 15 782 vs (2) 10 563                                                     NA
  Gupta et al \[[@R82]\]                Kingdom of Saudi Arabia                          Diabetes        Patients with diabetes                                                                               Management               Total direct cost (treatment, management and complication) of switching from (1) biphasic human insulin 30, (2) insulin glargine to biphasic insulin aspart 30   \(1\) 53 128-53 575 and (2) 61 569-52 849                                      NA
  Al-Kaabi & Atherton \[[@R79]\]        Qatar                                            Diabetes        NA                                                                                                   Management               Total direct and indirect cost including personal medical; non-medical costs, and income losses                                                                  500 billion in 2010, expected to reach 745 billion in 2030                     NA
  Shafie et al \[[@R77]\]                    (1) Algeria & (2) Kingdom of Saudi Arabia   Diabetes        Patients with diabetes                                                                               Management               Total cost (treatment, management and complication) of switching from glucose lowering drugs only to it coupled with biphasic insulin aspart 30 per patient      \(1\) 11 880 to 16 831 and (2) 51 158 to 49 263                                NA
  Lamri et al \[[@R73]\]                Algeria                                          Diabetes        NA                                                                                                   Management               Total annual spending on diabetes care for the health system                                                                                                     513 million                                                                    NA
  **Chronic respiratory diseases:**                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Aďt-Khaled et al \[[@R32]\]           Algeria and Syria                                Asthma          Pharmacies                                                                                           Treatment (long term)    Annual cost per a persistent mild, moderate or severe case                                                                                                       32, 52 and 92 respectively in Algeria; 104 for a moderate case in Syria        2
  Behbehani and Al-Yousifi \[[@R35]\]   Kuwait                                           Asthma          Heads of primary health care centers                                                                 Medications              Annual cost per a moderate case (using inhaled steroids and short-acting beta-agonists only)                                                                     562                                                                            3
  AlMarri \[[@R39]\]                    Qatar                                            Asthma          Asthma hospitalized patients                                                                         Hospital admission       Average cost per admission                                                                                                                                       1544                                                                           3
                                        Sultanate of Oman                                Asthma          Asthma patients                                                                                      Treatment                Total annual direct cost of treatment including medications                                                                                                      159 900 761                                                                    NA
                                        Morocco                                          Asthma          Individuals purchasing anti-asthmatic drugs                                                          Treatment                Average monthly cost of anti-asthmatic treatment between 1999 and 2010                                                                                           \[16.42-12.36\]                                                                NA
                                        Kuwait                                           Asthma          Patients (adults and children) with asthma                                                           Treatment                Total annual direct cost of treatment including outpatient, emergency and inpatient visits and medications                                                       208 244 564                                                                    NA
  Al-Kaabi & Atherton \[[@R79]\]        Qatar                                            COPD            NA                                                                                                   Treatment                Total direct and indirect cost including personal medical; non-medical costs, and income losses                                                                  2.1 trillion in 2010 expected to reach 4.8 trillion in 2030                    NA
  Al-Busaidi et al \[[@R78]\]           Sultanate of Oman                                Asthma          NA                                                                                                   Management               Total annual cost of asthma management                                                                                                                           159 741 021                                                                    NA
  Ghanname et al \[[@R72]\]             Morocco                                          Asthma          NA                                                                                                   Medications              Total annual cost of anti-asthmatic drugs                                                                                                                        24 361 920                                                                     NA
  Alzaabi et al \[[@R71]\]              United Arab Emirates                             Asthma          Asthma patients                                                                                      Treatment                Total direct cost of per patient mainly outpatient visits                                                                                                        207                                                                            2

\*N/A refers to "not applicable" whereby the data of interest is not specified in the respective reference.

A smaller scale study from Lebanon \[[@R37]\], conducted at a primary health care center in Beirut, estimated the direct cost of treating a fully compliant patient with diabetes mellitus type 2 to be US\$ 125 ([**Table 3**](#T3){ref-type="table"}). Direct cost calculations included costs of physician services, laboratory tests, drugs, inpatient care and emergency visits. Cost per patient attending the primary health care center was found to be lower than the estimated direct health care cost of US\$ 481 for a fully compliant diabetes mellitus type 2 patient attending private clinics at a tertiary medical care center in Lebanon.

In a national cross-sectional survey conducted in Saudi Arabia, Alhowaish (2013) estimated the total annual national health expenditure to be US\$ 0.9 billion, which represents around 21% of the country's total health expenditure \[[@R56],[@R64]\]. This figure is not restricted to only direct medical costs associated with management of diabetes in Saudi Arabia. Another study examined annual direct costs of diabetes at the national level and estimated the amount to be between US\$ 400 to 700 million \[[@R43]\]. In comparison, a study from Qatar showed that direct and indirect medical cost of diabetes management, including personal medical expenses, nonmedical costs and income losses reached US\$ 500 billion in 2010 and projections showed an expected rise to US\$ 745 billion in 2030 due to several factors \[[@R79]\].

Asthma
------

Two studies from Kuwait quantified costs associated with treating asthma ([Table 3](#T3){ref-type="table"}). The first determined the annual cost of asthma medications, based on severity, while the second evaluated direct costs of treating asthma at the national level and determined direct costs associated with emergency department visits, outpatient clinic visits, and asthma medications \[[@R35],[@R70]\]. Behbehani & Al-Yousifi (2003) calculated that the annual cost of a year's supply of medications for a moderate asthma case was equivalent to US\$ 562; cost of medications for a severe persistent case of asthma was found to be almost equivalent to the monthly salary of a nurse working in Kuwait \[[@R35]\]. Khadadah (2013), in a more recent study, estimated the annual cost of treating asthma cases among Kuwaiti nationals attending government health care facilities in Kuwait \[[@R70]\]. The estimated cost of treating asthma cases among Kuwaiti nationals was US\$ 208 244 564, with the greatest cost drivers being inpatient hospital stays and emergency department visits, while medications constituted only 7% of total direct costs of treatment \[[@R70]\].

DISCUSSION
==========

As NCDs' burden in the Arab region continues to grow, it becomes more necessary to assess the impact (financial and economic) of NCDs on patients and governments. In this review, studies providing quantification of costs associated with NCDs in 22 Arab countries, their treatment, management, or risk factors were included. The review identified and summarized only 55 studies covering the 16-year period (2000-2016). Costing studies were derived from LMICs like Sudan, Palestine, and Morocco, upper-middle-income countries and HICs, with four studies covering multiple countries in the Arab region \[[@R74]-[@R76],[@R89]\]. All four classes of major NCDs \[[@R5]\], including diabetes, asthma, cancer and cardiovascular diseases were evaluated, and costs were determined for treatment or management of diseases, at the societal, governmental, provider, or patient level.

The studies were classified by costing variables such as costing approach, costing perspective, types of costs, and sources of information, although many of the studies did not indicate the method of costing used, nor specify the types of costs included. Furthermore, there was a large variation in the methods used to quantify NCDs' costs in these countries. This lack of standardization made it difficult to conduct any type of cross-country, intra-country, or international comparisons. Any kind of cross-country comparison was further impeded by a focus, in the majority of identified studies, on treatment or management of only one class or type of NCD, with the exception of one study from Lebanon, which looked at costs of all smoking-related NCDs \[[@R89]\]. Also limiting cross-country and intra-country comparisons was inclusion of only one or a few variables of cost in calculations, with almost no calculations of the costs of NCDs covered in their totality. As such, it was not possible to identify trends in the costs of NCD management for Arab countries. Only three studies from Morocco used similar methodologies to quantify the costs of different classes of cancer to the Moroccan government \[[@R52],[@R59],[@R61]\]. These studies were also among the most comprehensive in their calculations, looking at different disease stages, and considering the incidence of the disease, and the different treatment modalities \[[@R52],[@R59],[@R61]\]. Even in the latter case, the heterogeneity in the cost calculation did not allow for trend identification. Nevertheless, the use of a semi-standardized method to quantify the direct costs of the different types of cancer in Morocco had its advantages. It allowed authors to make comparisons with international countries at an individual treatment level, allowed them to make comparisons to the Ministry of Health budgets, both at national and regional levels, and to make comparisons to national income levels \[[@R52],[@R59],[@R61]\]. In all cases, the direct cost of treatment was found to be higher than national budgets, higher than minimum income, but lower than the cost in countries used for comparison, pointing to the heavy burden that cancer treatment places on individuals and governments \[[@R52],[@R59],[@R61]\]. Such comprehensive results are useful for governments and decision-makers when allocating budgets and prioritizing funding to health facilities \[[@R52],[@R59],[@R61]\]. Yet studies from Morocco failed to look at cancer cost in its totality, and excluded crucial variables like indirect costs, productivity loss, and costs associated with outpatient treatment; therefore, costs obtained are likely an underestimation of the true cost of this NCD \[[@R52],[@R59],[@R61]\]. This was a common problem across most studies included in this review. Other methodological limitations identified from the studies included the use of different sampling frames and study designs, due to the epidemiological nature of the majority of the studies included. At the individual country level, instability, data scarcity, and struggling health care (information) systems could explain the variation in the data available to measure costs of NCDs, and thus the varying methodologies used \[[@R90],[@R91]\].

The closest comparison to findings can be extracted from studies conducted in HICs, and from members of Organization for Economic Co-operation and Development (OECD). One such study looked at NCDs' impact on national health expenditure \[[@R92]\]. Researchers found for the majority of included countries that NCDs accounted for at least one third of countries' national health expenditure \[[@R92]\]. This analysis was possible because these countries, mostly OECD members, used a national health account framework for analysis \[[@R92]\]. The availability of standardized data on costs from these countries even made it possible to compare expenditure at two different time periods \[[@R92]\]. Among those studies identified in this review, few considered the time horizon when assessing the costs of NCDs, A systematic review that looked at NCDs' global impact on health care spending and national income, mostly for countries in the American and European WHO regions, found that global health care expenditure on NCDs was increasing with time; furthermore, NCDs were resulting in national income losses \[[@R93]\]. However, this review only included one country from the Arab region \[[@R93]\]. For the most part, other reviews focusing on NCDs' costs to individuals and households suffered from similar methodological limitations as those identified in this review \[[@R29],[@R88]\].

Limitations
-----------

Due to the fact that our study was part of a larger epidemiological approach scoping review, the included studies analyzed in this review are subject to several limitations including absence of a clear definition of costing method used, wide heterogeneity in methods followed to calculate same and different types of cost and variation in case definition. Other limitations are related to missing data on patient characteristics, which could have affected care or cost, sample representativeness like exclusion of individuals not seeking care for financial reasons and uneven geographical distribution. There are also differences between health systems in Arab countries, affecting the allocation of health funds for NCDs' management. These factors did not allow us to pool reported cost estimates, to generalize results or to generate comparisons across studies. Another limitation is the search language used. This review only identified studies published in English, or containing an English abstract or keywords, potentially impacting number of studies identified and included in the review.

CONCLUSIONS
===========

The burden of NCDs in the Arab region is set to continue growing, conforming to local and global trends. This scoping review on the costs of NCDs in Arab region sheds light on an important issue: although NCDs-related morbidity and mortality continue to rise in all Arab countries across different income levels, data on costing remains limited by this type of evidence's paucity and the generally low quality of studies published in this area. Internationally, NCDs resulted in high health care costs for governments and in great out-of-pocket and catastrophic health expenditures for households. Still, global findings and trends regarding NCDs raises questions of representativeness when inferring about applicability in the local and regional context. Moreover, even at international levels, questions persist concerning methodologies used for inferring costs at the national level.

Furthermore, although this review represents the most comprehensive to-date assessment of studies in the region directly quantifying the costs of NCDs, it remains restricted by the paucity of evidence and the generally low to very-low quality of included studies. Hence, if decisions are to be made based on available rough estimates, resources might be used inefficiently.

This research represents a foundational step for policymakers in need of evidence when managing the financial burden of NCDs in future reforms. There is also a need for future studies, of improved and harmonized methodology, from the Arab region on the cost management of NCDs and their growing financial impact at household and governmental levels.
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